A brief account of various treatment modalities for COVID-19 infections
Keywords:COVID-19, Vaccine, Hydroxychloroquine, Remdesivir
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and has a case fatality rate of 2-3%, with higher rates among elderly patients and patients with comorbidities. It was determined in a study that the viral load peaked during the first week of illness and then gradually declined over the second week. Viral load also correlates with age and the existent of comorbidities. Furthermore, both IgG and IgM antibodies starts to increase by around day 10 after symptomatic onset and most patients had seroconversion within the first 3 weeks. This hints at the fact that the patients are most infectious during the first week of infection and also accounts for the high transmissibility of SARS-CoV-2 during this period
Chen Y, Li L. SARS-Cov-2: Virus dynamics and host response. Available at: https://doi.org/10.1016/ S1473-3099(20)30235-8. Accessed on 23 March 2020.
WHO: - Transmission of SARS-CoV-2: implications for infection prevention precautions. Available at: https://www.who.int/news-room/commentaries /detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions. Accessed on 09 July 2020.
Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Available at: https://pmj.bmj.com/ content/early/2020/05/28/postgradmedj-2020-137785. Accessed on 15 April 2020.
Li X, Wang Y, Agostinis P, Rabsen A, Melino G, Carafoli E, Shi Y, Sun E. Is Hydroxychloroquine beneficial for COVID-19 patients? Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341710/#__ffn_sectitle. Accessed on 08 July 2020.
Liu A. End of the road for Hydroxychloroquine. Available at: https://www.fiercepharma. com/pharma/end-road-for-hydroxychloroquine-covid-19-as-novartis-nih-and-who-pull-out-trials. Accessed on 22 July 2020.
WHO. Q & A: why was hydroxychloroquine stopped in the solidarity trial. Available at: https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-and-covid-19. Accessed on 19 July 2020.
Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, Giarratano A, Einav S, Cecconi M. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021;27(1):52-66.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020;6(10):1192-8.
Sina S, Irvani N. Favipiravir in hospitalized Covid-19 patients (FIC). Available at: https://clinicaltrials.gov/ct2/show/NCT04359615. Accessed on 28 April 2020.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382(24):2327-36.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460-70.
Sun M, Xu Y, He H, Zhang L, Wang X, Qiu Q, et al. A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis. 2020;98:334-46.
Mokobi F. Dexamethasone- properties, uses, side-effects and COVID-19. Available at: microbenotes.com/dexamethasone/#dexamethasone-and-covid-19. Accessed on 28 April 2020.
World's 'first' COVID-19 vaccine Sputnik V out in Russia: How it works and who will get it? Available at: https://www.livemint.com/news/india/world-s-first-covid-19-vaccine-out-in-russia-how-it-works-and-who-will-get-it-11597143985840.html. Accessed on 28 April 2020.
Strange case of Russia’s Sputnik 5 Covid-19 vaccine. Available at: https://timesofindia.indiatimes.com/ blogs/methink/strange-case-of-russias-sputnik-5-covid-19-vaccine/. Accessed on 28 April 2020.
Coronavirus vaccine update: Pfizer and BNTECH start dosing patients. Available at: https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/coronavirus-vaccine-update-pfizer-and-bntech-start-dosing-patients/articleshow /75806928.cms. Accessed on 28 April 2020.
Rees V. (European Pharmaceutical Review): - Germany to begin first clinical trials of Covid-19 vaccine candidate. Available at: https://www.europeanpharmaceuticalreview.com/news/117624/germany-to-begin-first-clinical-trial-of-covid-19-vaccine-candidate/. Accessed on 28 April 2020.
Charles R. BNT-162 SARS-CoV-2 Vaccine. Available at: https://www.precisionvaccinations. com/vaccines/bnt162-sars-cov-2-vaccine. Accessed on 28 April 2020.
BioNTech SE (BioNTech RNA Pharmaceuticals Gmbh): - A Trial Investigating the Safety and Effects of Four BNT162 Vaccines against COVID-2018 in Health Adults. Available at: https://clinica ltrials.gov/ct2/show/NCT04380701. Accessed on 28 April 2020.
Pfizer-BioNTech COVID-19 vaccine shows positive results, on track for regulatory review in October. Available at: https://www.timesnownews.com/ health/article/pfizer-biontech-covid-19-vaccine-shows-positive-results-on-track-for-regulatory-review-in-october/640710.
Moderna’s Work on our COVID-19 Vaccine. Available at: https://www.modernatx.com/ modernas-work-potential-vaccine-against-covid-19. Accessed on 28 April 2020.
NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies. Available at: https://www.nih.gov/news-events/news-releases/nih-moderna-investigational-covid-19-vaccine-shows-promise-mouse-studies. Accessed on 20 September 2020.
Interim data for Covid-19 vaccine AZD-1222 and its antibody and T-cell responses. Published by AstraZeneca PLC. Available at: https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-i-ii-trial.html. Accessed on 20 July 2020.
Carlson R. AZD1222 SARS-CoV-2 Vaccine description. Available at: https://www.precision vaccinations.com/vaccines/azd1222-sars-cov-2-vaccine. Accessed on 20 July 2020.
Datta R. COVID-19: New Results Shine Ray of Hope on Vaccine Development Efforts. Available at: https://science.thewire.in/the-sciences/covid-19-vaccine-trials-oxford-astrazeneca-moderna-biontech/. Accessed on 23 July 2020.
China's Sinovac says coronavirus vaccine has shown positive results in trials. Available at: https://www.livemint.com/science/health/china-s-sinovac-says-coronavirus-vaccine-has-shown-positive-results-in-trials-11592103590078.html. Accessed on 23 July 2020.
HospiMedica International Staff Writers: - Sinovac Biotech Phase 3 trials Of Covid-19 Vaccine Candidate in Brazil. Available at: https://www.hospimedica.com/covid-19/articles/294783405/chinas-sinovac-biotech-begins-phase-3-trials-of-coronavirus-vaccine-candidate-in-brazil.html. Accessed on 10 July 2020.
Explained: What is Covaxin, India’s Covid-19 vaccine candidate; how long before approval? Available at: https://indianexpress.com/article /explained/explained-what-is-covaxin-indias-covid-19-vaccine-candidate-how-long-before-approval-6483553/. Accessed on 23 July 2020.
COVID Vaccine: Bharat Biotech Allowed to Test Covaxin Administration Through Skin. Available at: https://www.india.com/news/india/covid-vaccine-bharat-biotech-allowed-to-test-covaxin-administration-through-skin-4119710/. Accessed on 23 July 2020.
How SARS-CoV-2 causes disease and death in covid-19. The Economist. Available at: https://www.economist.com/briefing/2020/06/06/how-sars-cov-2-causes-disease-and-death-in-covid-19. Accessed on 06 June 2020.
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;382(25):2411-8.
Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18:164.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe Covid-19: a randomised, double-blind, placebo controlled, multicentric trial. The Lancet. 2020;395(10236):1569-78.
Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
Lammers T, Sofias AM, van der Meel R, Schiffelers R, Storm G, Tacke F, Koschmieder S, Brümmendorf TH, Kiessling F, Metselaar JM. Dexamethasone nanomedicines for COVID-19. Nat Nanotechnol. 2020;15(8):622-4.